We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials ...

Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday reported topline results from two pivotal Phase 3 trials evaluating the company's drug candidate islatravir in combination with its approved HIV drug ...